1
There are thousands of natural and synthetic antibiotics, relatively few of which have been tested and marketed. The most commonly used are as follows:
2
A. L. Bisno, “Staphylococcal Endocarditis and Bacteremia,”
Hospital Practice
, April 15, 1986: 139â58.
3
A. L. Panililo, D. H. Culver, R. P. Gaynes, et al., “Methicillin-Resistant
Staphylococcus aureus
in U.S. Hospitals, 1975â1991,”
Infection Control and Hospital Epidemiology
13 (1992): 582â86.
4
M. Truneh, “Phage Types and Drug Susceptibility Patterns of
Staphylococcus aureus
from Two Hospitals in Northwest Ethiopia,”
Ethiopian Medical Journal
29 (1991): 1â6.
5
E. E. Udo and W. B. Grubb, “Transfer of Resistance Determinants from a Multi-Resistant
Staphylococcus aureus
Isolate,”
Journal of Medical Microbiology
35 (1990): 72â79.
6
For overviews of the antibiotic resistance crisis, see M. L. Cohen, “Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era,”
Science
257 (1992): 1050â55; S. M. Finegold, “Antimicrobial Therapy of Anaerobic Infections: A Status Report,”
Hospital Practice,
October 1979: 71â81; L. O. Gentry, “Bacterial Resistance,”
Orthopedic Clinics of North America
22 (1991): 379â88; A. Gibbons, “Exploring New Strategies to Fight Drug-Resistant Microbes,”
Science
257 (1992): 1036â38; M. Lappe,
Germs That Won't Die
(Garden City, NY: Anchor Press, 1982); S. B. Levy,
The Antibiotic Paradox
(New York: Plenum Press, 1992); H. C. Neu, “The Crisis in Antibiotic Resistance,”
Science
257 (1992): 1064â73; Panlilio et al. (1992), op. cit.; and M. Toner, “When Bugs Fight Back,” Pulitzer Prize-winning series of reports in the
Atlanta Constitution
, August 23, 1992âOctober 16, 1992.
7
D. P. Levine, B. S. Fromm, and B. R. Reddy, “Slow Response to Vancomycin or Vancomycin Plus Rifampin in Methicillin-Resistant
Staphylococcus aureus
Endocarditis,”
Annals of Internal Medicine
115 (1991): 674â80.
8
D. S. Kernodle and A. B. Kaiser, “Comparative Prophylactic Efficacy of Cefazolin and Vancomycin in a Guinea Pig Model of
Staphylococcus aureus
Wound Infection,”
Journal of Infectious Diseases
168 (1993): 152â57; and R. P. Wenzel, “Preoperative Antibiotic Prophylaxis,”
New England Journal of Medicine
326 (1992): 337â39.
In Denmark, where national medical registries are excellent because all the nation's citizens receive their health care from the federal government, a review of the country's meningitis cases from 1986 to 1989 revealed that 104 people had suffered the severe ailment as a result of staphylococcal infection. Sixty-one of the cases were acquired in the hospital following surgery. Fortunately, none of the Danish cases was MRSA, but all involved some degree of penicillin resistance. See A. G. Jensen, F. Esperson, P. Skinhøj, et al.,
“Staphylococcus aureus
Meningitis,”
Archives of Internal Medicine
153 (1993): 1902â8.
9
Bacterial subtypes 29/52/80/95 in Detroit; 29/77/83A/85 in Boston. See L. R. Crane, D. P. Levine, M. J. Zervos, and G. Cummings, “Bacteremia in Narcotic Addicts at the Detroit Medical Center: I. Microbiology, Epidemiology, Risk Factors, and Empiric Therapy,”
Review of Infectious Diseases
8 (1986): 364â73; and D. E. Craven, A. I. Rixinger, T. A. Goularte, and W. R. McCabe, “Methicillin-Resistant
Staphylococcus aureus
Bacteremia Linked to Intravenous Drug Abusers Using a âShooting Gallery,'”
American Journal of Medicine
80 (1986): 770â76.
10
Udo and Grubb (1990), op. cit.
11
B. Kreiswirth, J. Kornblum, R. D. Arbeit, et al., “Evidence for a Clonal Origin of Methicillin Resistance in
Staphylococcus aureus,” Science
259 (1993): 227â30.
12
For an overview of the global penicillin resistance trends, for example, see C. C. Sanders and W. E. Sanders, Jr., “Beta-Lactam Resistance in Gram-Negative Bacteria: Global Trends and Clinical Impact,”
Clinical Infectious Diseases
15 (1992): 824â39.
15
C. E. Phelps, “Bug/Drug Resistance: Sometimes Less Is More,”
Medical Care
27 (1989): 194â203.
16
D. L. Stevens, M. H. Tanner, J. Winship, et al., “Severe Group A Streptococcal Infections Associated with a Toxic Shock-like Syndrome and Scarlet Fever Toxin,”
New England Journal of Medicine
321 (1989): 1â7.
17
K. Wright, “Bad News Bacteria,”
Science
249 (1990): 22â24.
18
H. C. Dillon, and C. W. Derrick, Jr., “Streptococcal Complications: The Outlook for Prevention,”
Hospital Practice
, September 1972: 93â101.
19
S. P. Gotoff, “Emergence of Group B Streptococci as Major Perinatal Pathogens,”
Hospital Practice
, September 1977: 85â90.
21
Centers for Disease Control, “Prevalence of Penicillin-Resistant
Streptococcus pneumoniae
âConnecticut, 1992â1993,”
Morbidity and Mortality Weekly Report
43 (1994): 216â23.
22
A survey of 748 cardiac patients treated in Johannesburg, South Africaâall of whom were poor blacks who had suffered childhood bouts of rheumatic feverâillustrated the severity of heart disease produced by the bacteria. Under the apartheid state, black South Africans lived in conditions of acute squalor and health care deprivation. As a result, during the 1980s rheumatic fever was about as common among black South Africans as it had been among white urban Americans in 1920. And like their 1920s counterparts in the United States, black South Africans who survived rheumatic fever during early childhood had a better than 50 percent chance of facing life-threatening heart disease before their twentieth birthday. The primary cause of their cardiac difficulties was mitral valve damage which required open-heart surgery. R. H. Marcus, P. Sareli, W. A. Pocock, and J. B. Barlow, “The Spectrum of Severe Rheumatic Mitral Valve Disease in a Developing Country,”
Annals of Internal Medicine
120 (1994): 177â83.
Dealing surgically with rheumatic fever heart damage has been likened to “attempting to mop up the water on the floor while leaving the faucet open,” particularly in the context of poor countries. WHO during the 1990s instituted a trial program of rheumatic fever prevention in sixteen developing countries that involved training local paramedics to recognize streptococcal throat infections in children and treat the kids prophylactically with benzathine penicillin to prevent recurrent infections. M. J. McLaren, M. Markowitz, and M. A. Gerber, “Rheumatic Heart Disease in Developing Countries: The Consequence of Inadequate Prevention,”
Annals of Internal Medicine
120 (1994): 243â44.
23
L. G. Veasy, S. E. Wiedneier, G. S. Orsmond, et al., “Resurgence of Acute Rheumatic Fever in the Intermountain Area of the United States,”
New England Journal of Medicine
316 (1987): 421â27.
24
See “Streptococcal Diseases,” in A. S. Benenson, ed.,
Control of Communicable Diseases in Man
(Washington, D.C.: American Public Health Association, 1990), 411â18.
25
L. A. Haglund, G. R. Istre, D. A. Pickett, et al., “Invasive Pneumococcal Disease in Central Oklahoma: Emergence of High-Level Penicillin Resistance and Multiple Antibiotic Resistance,”
Journal of Infectious Diseases
168 (1993): 1532â35.
26
F. Shan, S. Germer, and D. Hazell, “Aetiology of Pneumonia in Children in Goroka Hospital, Papua New Guinea,”
Lancet
II (1981): 537â41.
27
World Health Organization, “Implementation of the Global Strategy for Health for All by the Year 2000, Second Evaluation; and Eighth Report on the World Health Situation,” report to the 45th World Health Assembly, Provisional Agenda Item 17, Geneva, 1992.
28
J. S. Spika, M. H. Munshi, B. Wojtyniak, et al., “Acute Lower Respiratory Infections: A Major Cause of Death in Children in Bangladesh,”
Annals of Tropical Pediatrics
9 (1989): 33â39; and B. J. Selwyn and BOSTID, “The Epidemiology of Acute Respiratory Tract Infection in Young Children: Comparison of Findings from Several Developing Countries,”
Review of Infectious Diseases
12 (1990): S870âS888.
29
World Health Organization, “Acute Respiratory Infections in Children: Case Management in Small Hospitals in Developing Countries,” Program for the Control of Acute Respiratory Infections, Geneva, 1990.